Clinical outcome of patients with recurrent or refractory localized Ewing's sarcoma family of tumors: A retrospective report from the Japan Ewing Sarcoma Study Group.

ABSTRACT:

Background

Patients with Ewing's sarcoma family of tumors (ESFT) who experience relapse or progression have a poor prognosis.

Aim

This study aimed to identify the prognostic and therapeutic factors affecting overall survival (OS) of patients with recurrent or refractory localized ESFT.

Methods and results

Thirty-eight patients with localized ESFT who experienced first relapse or progression between 2000 and 2018 were retrospectively reviewed. The 5-year OS rate of the entire cohort was 48.3% (95% confidence interval, 29.9%-64.5%). Multivariate analysis of OS identified time to relapse or progression, but not stem cell transplantation (SCT), as the sole independent risk factor (hazard ratio, 35.8; P = .002). Among 31 patients who received salvage chemotherapy before lo

SUBMITTER: Umeda K 

PROVIDER: S-EPMC8222563 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature